In the past decade, the emergence of novel drugs that target signalling pathways activated by genetic changes, for example, EGFR mutations and ALK rearrangement status, has revolutionized the treatment of NSCLC patients (3). The gene discussed is ALK; the disease is non-small cell lung carcinoma.